Skip to content

Development, validation and clinical testing of tension headache assessment tool (THAT) for evaluation of tension type headache

Development, validation and clinical testing of tension headache assessment tool (THAT) for evaluation of + C4 C2,1 tension type headache

Status
Recruiting
Phases
Phase 1
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/04/065174
Enrollment
210
Registered
2024-04-03
Start date
Unknown
Completion date
Unknown
Last updated
2024-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G892- Chronic pain, not elsewhere classified

Interventions

Intervention1: Evaluation of the diagnostic & therapeutic approach for primary tension headache: The neurological examination is conducted to conform evaluation of headache under the guideline of ICHD
headaches for less than one day per month on average or less than 12 days per year), frequent ETTH (headaches for between one and fourteen days per month or between 12 and 180 days per year), and chro

Sponsors

lovely professional university
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age 35-45 2. both sexes 3. Patient suffering from TTH, stress headache, according to headache diary headache turn into migraine without aura, nausea. 4. limited neck rom 5. neck stiffness, new heavy head, 6. Accurate anamnesis and accurate physical examination will help in diagnosing the etiology of headache 7. Orthopedic disorder that impaired functional neck trunk rom 8. Family history, personal history. 9. The participant has a prior history of headache (s) lasting 6 weeks or longer, when untreated. 10. The participants has episodic headache as define by international headache society international classification with an adequately documented history of headache at least 12 months. 11. The participant has experienced failure on a previous treatment targeting the calcitonin gene-related peptide (CGRP) pathway (anti-CGRP monoclonal antibodies [mAbs] and gepants) 12. Participants have prolong use of medication, analgesic, etc.

Exclusion criteria

Exclusion criteria: • 1. Temperature elevation, fever, vomiting, migraine with aura etc. 2. CH include severe unilateral orbital, supraorbital and/or temporal pain lasting from 15 minutes to 180 minutes 3. The inclusive criteria were not answering the scales and not signing the informed consent. 4. The History of significant to the head and neck surgery. 5. History of head and cervical region surgery. 6. Subject with another history of neurological problem 7. Vestibular suppressant medication, and condition, dizziness etc. 8. systemic diseases 9. Fibromyalgia 10. Skin rashes 11. meningitis 12. peripheral neuropathies 13. craneomandibular dysfunctions 14. recent trauma 15. chirurgic interventions in neck or facial 16. osteoporotic spine 17. vitamin d deficiency 18. complex regional pain syndrome 19. alcohol intoxication 20. vestibular neuritis 21. bilateral and central vestibular disorder 22. Participants with a lifetime history of psychosis, bipolar mania, or dementia are excluded. Participants with other psychiatric conditions whose symptoms are not controlled or who have not been adequately treated for a minimum of 6 months prior to Screening Visit 2 are also excluded. 23. The participant has a history of clinically significant cardiovascular disease, including uncontrolled hypertension, ischaemia or thromboembolic events (for example, cerebrovascular accident, deep vein thrombosis, or pulmonary embolism). 24. The participant has a history or diagnosis of hypnic headache, hemicrania continua, new daily persistent headache, chronic migraine or unusual migraine subtypes such as hemiplegic migraine (sporadic and familial), recurrent painful ophthalmoplegic neuropathy, migraine with brainstem aura and migraine with neurological accompaniments that are not typical of migraine aura (diplopia, altered consciousness, or long duration). 25. The participant is, at Screening Visit 2, at significant risk of suicide.

Design outcomes

Primary

MeasureTime frame
THAT ASSESMENT TOOLTimepoint: ASSESMENT FOR 4 WEEK AND FOLLOW UP FOR 6 WEEKS

Secondary

MeasureTime frame
BLOOD MARKERSTimepoint: 1 week & after 4 week

Countries

India

Contacts

Public ContactAshu Rani

LOVELY PROFFESIONAL UNIVERSITY

shantha.27713@lpu.co.in07904850120

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026